ClinicalTrials.gg
TerminatedNCT04575584Updated Jan 17, 2023Results posted

Efficacy and Safety of Molnupiravir (MK-4482) in Hospitalized Adult Participants With COVID-19 (MK-4482-001)

A Phase 2/3 interventional study of Molnupiravir and Placebo in Coronavirus Disease (COVID-19), sponsored by Merck Sharp & Dohme LLC. Terminated at 89 sites in 17 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-01-17.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2/3, Interventional, and Treatment

Why this study was terminated
Business reasons

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
304
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 14 studies testing molnupiravir in COVID-19 — 4 open to participants now, 4 under way, 2 of them phase 3. molnupiravir · COVID-19.

Enrollment
7th of 14
304 · median 275
Started
2020
with 4 others
Phase 2/3
3 of 14
none open now
Registered
3rd of 14
by date
Lead sponsor
5 of 14
Merck Sharp & Dohme LLC

Among the 14 studies testing molnupiravir in COVID-19, this one is the 7th largest by enrollment, is one of 5 that started in 2020, is one of 3 in phase 2/3, and was the 3rd registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 467 are open to participants now.

Browse COVID-19 studies →

Open to participants now

4 of the 14 studies testing molnupiravir in COVID-19 are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About molnupiravir

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing molnupiravir in COVID-19, or all of them as a file.
02

Study summary

This study aims to evaluate the safety, tolerability and efficacy of molnupiravir (MK-4482) compared to placebo. The primary hypothesis is that molnupiravir is superior to placebo as assessed by the rate of sustained recovery through Day 29.

Read the detailed description

This study was intended to include two parts: Part 1 was a dose-ranging phase 2 study, and Part 2 was a phase 3 study to evaluate the dose selected in Part 1. However, this study was terminated due to business reasons prior to conducting Part 2. Participants in Part 1 were followed until Month 7.

03

Conditions studied

  • Coronavirus Disease (COVID-19)

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has documentation of polymerase chain reaction (PCR)-confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection with sample collection ≤ 10 days prior to the day of randomization. PCR is the preferred method; however other diagnostic methods are allowed if authorized by use in the country
  • Had initial onset of signs/symptoms attributable to COVID-19 for ≤10 days prior to the day of randomization and ≥1 sign/symptom attributable to COVID-19 present at randomization
  • Requires medical care in the hospital for ongoing clinical manifestations of COVID-19 (not just for public health or quarantine purposes)
  • Has mild, moderate, or severe COVID-19
  • Is willing and able to take oral medication
  • Males agree to the following during the intervention period and for at least 90 days after the last dose of study intervention: Refrain from donating sperm; and either abstain from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent; or must agree to use
  • Females are not pregnant or breastfeeding, and at least one of the following conditions applies: Is not a woman of child bearing potential (); or is a WOCBP and using a contraceptive method that is highly effective (a low user dependency method OR a user dependent method in combination with barrier method), or be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis) for 28 days from the start of study intervention; a WOCBP must have a negative highly sensitive pregnancy test (serum test is required) within 24 hours before the first dose of study intervention

Exclusion criteria

Exclusion Criteria:

  • Has critical COVID-19 with any of the following: respiratory failure (including endotracheal intubation and mechanical ventilation, oxygen delivered by high-flow nasal cannula (flow rates >20L/min with fraction of delivered oxygen ≥ 0.5), noninvasive positive pressure ventilation, or extracorporeal membrane oxygenation (ECMO))
  • Is on dialysis or has reduced estimated (eGFR) \<30 mL/min/1.73m\^2 by the Modification of Diet in Renal Disease (MDRD) equation
  • Has any of the following conditions: (HIV) with a recent viral load >50 copies/mL or cluster of differentiation 4 (CD4) \<200 cell/mm\^3; chemotherapy required within 6 weeks before randomization; a neutrophilic granulocyte absolute count \<500/mm\^3; or allogeneic hematopoietic stem cell transplant recipient
  • Has history of or infection with any of the following: 1) cirrhosis 2) end-stage liver disease 3) hepatocellular carcinoma 4) (AST) and/or alanine aminotransferase (ALT) > 3 times the at screening
  • Has a history of acute pancreatitis within 3 months prior to randomization or a history of chronic pancreatitis
  • Is taking or is anticipated to require any prohibited therapies
  • Is unwilling to abstain from participating in another interventional clinical trial through Day 29 with an compound or device, including those for COVID-19 therapeutics
  • Is anticipated to require transfer to a non-study hospital within 72 hours
  • Has a baseline heart rate of \< 50 beats per minute at rest
  • Has a count \<100,000/μL or received a platelet transfusion in the 5 days prior to randomization
  • Has or other to any of the components of the study interventions as determined by the investigator
  • Has any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant or that could prevent, limit, or confound the protocol-specified assessments including but not limited to: participants who are not expected to survive longer than 48 hours after randomization or participants who are expected to require mechanical ventilation within 48 hours after randomization or participants with a recent history of mechanical ventilation or participants with conditions that could limit gastrointestinal absorption of capsule contents
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
304 participants (actual)

Study arms

  • Experimental
    Part 1: Molnupiravir 200 mg

    200 mg molnupiravir administered orally every 12 hours for 5 days (10 doses total)

    Drug: Molnupiravir

  • Experimental
    Part 1: Molnupiravir 400 mg

    400 mg molnupiravir administered orally every 12 hours for 5 days (10 doses total)

    Drug: Molnupiravir

  • Experimental
    Part 1: Molnupiravir 800 mg

    800 mg molnupiravir administered orally every 12 hours for 5 days (10 doses total)

    Drug: Molnupiravir

  • Placebo comparator
    Part 1: Placebo

    Placebo matching molnupiravir administered orally every 12 hours for 5 days (10 doses total)

    Drug: Placebo

  • Experimental
    Part 2: Molnupiravir

    Molnupiravir (dose to be selected) administered orally every 12 hours for 5 days (10 doses total)

    Drug: Molnupiravir

  • Placebo comparator
    Part 2: Placebo

    Placebo matching molnupiravir administered orally every 12 hours for 5 days (10 doses total)

    Drug: Placebo

Interventions

  • Molnupiravir administered orally in capsule form every 12 hours for 5 days (10 doses total)

  • DrugPlacebo

    Placebo matching molnupiravir administered orally in capsule form every 12 hours for 5 days (10 doses total)

06

What researchers measure

Primary outcomes

  1. Time-to-sustained Recovery

    The median time to sustained recovery is reported. Sustained recovery is defined as 1) the participant is alive and not hospitalized; or 2) the participant is alive and medically ready for discharge as determined by the investigator.

    Time frame: Up to 29 days

  2. Number of Participants With an Adverse Event (AE)

    The number of participants with at least 1 AE is presented. An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: Up to 19 days (during treatment and 14-day follow-up)

  3. Number of Participants Who Discontinued Study Intervention Due to an AE

    The number of participants discontinuing from study treatment due to an AE is presented. An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: Up to 5 days

Secondary outcomes

  1. Number of Participants With All-cause Mortality

    The number of participants with all-cause mortality through Day 29 is presented. All-cause mortality is defined as death due to any cause. Any participants with an unknown survival status at Day 29 were imputed as deceased.

    Time frame: Up to 29 days

  2. Odds of a More Favorable Response on Pulmonary Ordinal Outcome Score on Day 3

    Pulmonary score is a score on an ordinal scale which focuses on respiratory sequalae based on oxygen requirements using 7 mutually exclusive categories. The score ranges from 1 ("can independently undertake personal usual activities with minimal or no symptoms") to 7 ("death") with a higher score indicating more severe respiratory sequalae. The number of participants at each score category is presented.

    Time frame: Day 3

  3. Odds of a More Favorable Response on Pulmonary Ordinal Outcome Score on End of Treatment (EOT [Day 5])

    Pulmonary score is a score on an ordinal scale which focuses on respiratory sequalae based on oxygen requirements using 7 mutually exclusive categories. The score ranges from 1 ("can independently undertake personal usual activities with minimal or no symptoms") to 7 ("death") with a higher score indicating more severe respiratory sequalae. The number of participants at each score category is presented.

    Time frame: EOT (Day 5)

  4. Odds of a More Favorable Response on Pulmonary Ordinal Outcome Score on Day 10

    Pulmonary score is a score on an ordinal scale which focuses on respiratory sequalae based on oxygen requirements using 7 mutually exclusive categories. The score ranges from 1 ("can independently undertake personal usual activities with minimal or no symptoms") to 7 ("death") with a higher score indicating more severe respiratory sequalae. The number of participants at each score category is presented.

    Time frame: Day 10

  5. Odds of a More Favorable Response on Pulmonary Ordinal Outcome Score on Day 15

    Pulmonary score is a score on an ordinal scale which focuses on respiratory sequalae based on oxygen requirements using 7 mutually exclusive categories. The score ranges from 1 ("can independently undertake personal usual activities with minimal or no symptoms") to 7 ("death") with a higher score indicating more severe respiratory sequalae. The number of participants at each score category is presented.

    Time frame: Day 15

  6. Odds of a More Favorable Response on Pulmonary Ordinal Outcome Score on Day 29

    Pulmonary score is a score on an ordinal scale which focuses on respiratory sequalae based on oxygen requirements using 7 mutually exclusive categories. The score ranges from 1 ("can independently undertake personal usual activities with minimal or no symptoms") to 7 ("death") with a higher score indicating more severe respiratory sequalae. The number of participants at each score category is presented.

    Time frame: Day 29

  7. Odds of a More Favorable Response on Pulmonary+ Ordinal Outcome Score on Day 3

    Pulmonary+ score is a score on an ordinal scale which is a 7-category assessment that captures the range of disease severity in hospitalized participants, including coagulation-related complications and respiratory dysfunction. The score ranges from 1 ("can independently undertake personal usual activities with minimal or no symptoms") to 7 ("death") with a higher score indicating more severe respiratory sequalae. The number of participants at each score category is presented.

    Time frame: Day 3

  8. Odds of a More Favorable Response on Pulmonary+ Ordinal Outcome Score on EOT (Day 5)

    Pulmonary+ score is a score on an ordinal scale which is a 7-category assessment that captures the range of disease severity in hospitalized participants, including coagulation-related complications and respiratory dysfunction. The score ranges from 1 ("can independently undertake personal usual activities with minimal or no symptoms") to 7 ("death") with a higher score indicating more severe respiratory sequalae. The number of participants at each score category is presented.

    Time frame: EOT (Day 5)

  9. Odds of a More Favorable Response on Pulmonary+ Ordinal Outcome Score on Day 10

    Pulmonary+ score is a score on an ordinal scale which is a 7-category assessment that captures the range of disease severity in hospitalized participants, including coagulation-related complications and respiratory dysfunction. The score ranges from 1 ("can independently undertake personal usual activities with minimal or no symptoms") to 7 ("death") with a higher score indicating more severe respiratory sequalae. The number of participants at each score category is presented.

    Time frame: Day 10

  10. Odds of a More Favorable Response on Pulmonary+ Ordinal Outcome Score on Day 15

    Pulmonary+ score is a score on an ordinal scale which is a 7-category assessment that captures the range of disease severity in hospitalized participants, including coagulation-related complications and respiratory dysfunction. The score ranges from 1 ("can independently undertake personal usual activities with minimal or no symptoms") to 7 ("death") with a higher score indicating more severe respiratory sequalae. The number of participants at each score category is presented.

    Time frame: Day 15

  11. Odds of a More Favorable Response on Pulmonary+ Ordinal Outcome Score on Day 29

    Pulmonary+ score is a score on an ordinal scale which is a 7-category assessment that captures the range of disease severity in hospitalized participants, including coagulation-related complications and respiratory dysfunction. The score ranges from 1 ("can independently undertake personal usual activities with minimal or no symptoms") to 7 ("death") with a higher score indicating more severe respiratory sequalae. The number of participants at each score category is presented.

    Time frame: Day 29

  12. Odds of a More Favorable Response in the Clinical Risk of Mortality Category From the National Early Warning Score

    The National Early Warning Score (Royal College of Physicians, 2012) assesses a participant's degree of illness as assessed by clinical risk prediction categories based on a set of vital sign measurements. There are 7 physiological parameters: respiration rate, oxygen saturation, supplemental oxygen, systolic blood pressure, pulse rate, level of consciousness, and temperature. A score of 0 to 3 was allocated to each parameter except supplemental oxygen use (score of 0 \[no\] or 2 \[yes\]) and level of consciousness (score of 0 or 3 with 0 = normal health condition and 3 = worst health condition). All scores were summed to get an aggregate score. Aggregate NEWS score ranged from 0 to 19, with higher scores meaning more severity/higher risk: low risk (score 0 to 4); low to medium risk (score of 3 in any individual parameter); medium risk (score 5 to 6); high risk (score 7 to 19). The number of participants at each aggregate risk category is presented.

    Time frame: EOT (Day 5)

  13. Odds of a More Favorable Response on WHO 11-point Ordinal Outcomes Score on a Scale on Day 3

    The World Health Organization (WHO) outcome scale is an 11-point ordinal score that categorizes clinical progression. Score ranges from 0 ("uninfected") to 10 ("dead") with higher score indicating clinical progression. The number of participants at each score category is presented.

    Time frame: Day 3

  14. Odds of a More Favorable Response on WHO 11-point Ordinal Outcomes Score on a Scale on EOT (Day 5)

    The World Health Organization (WHO) outcome scale is an 11-point ordinal score that categorizes clinical progression. Score ranges from 0 ("uninfected") to 10 ("dead") with higher score indicating clinical progression. The number of participants at each score category is presented.

    Time frame: EOT (Day 5)

  15. Odds of a More Favorable Response on WHO 11-point Ordinal Outcomes Score on a Scale on Day 10

    The World Health Organization (WHO) outcome scale is an 11-point ordinal score that categorizes clinical progression. Score ranges from 0 ("uninfected") to 10 ("dead") with higher score indicating clinical progression. The number of participants at each score category is presented.

    Time frame: Day 10

  16. Odds of a More Favorable Response on WHO 11-point Ordinal Outcomes Score on a Scale on Day 15

    The World Health Organization (WHO) outcome scale is an 11-point ordinal score that categorizes clinical progression. Score ranges from 0 ("uninfected") to 10 ("dead") with higher score indicating clinical progression. The number of participants at each score category is presented.

    Time frame: Day 15

  17. Odds of a More Favorable Response on WHO 11-point Ordinal Outcomes Score on a Scale on Day 29

    The World Health Organization (WHO) outcome scale is an 11-point ordinal score that categorizes clinical progression. Score ranges from 0 ("uninfected") to 10 ("dead") with higher score indicating clinical progression. The number of participants at each score category is presented.

    Time frame: Day 29

07

Results

Posted Aug 16, 2022

Participant flow

Participants were enrolled at 86 study centers in 15 countries.

Participant flow — Overall Study
MilestonePart 1: Molnupiravir 200 mgPart 1: Molnupiravir 400 mgPart 1: Molnupiravir 800 mgPart 1: PlaceboPart 2: MolnupiravirPart 2: Placebo
Started7575767800
Treated7373727500
Completed6160637000
Not completed141513800
Withdrew: Death646200
Withdrew: Lost to follow-up111100
Withdrew: Physician decision011100
Withdrew: Withdrawal by subject795300
Withdrew: Not recorded000100

Outcome measures

PrimaryTime-to-sustained Recovery

The median time to sustained recovery is reported. Sustained recovery is defined as 1) the participant is alive and not hospitalized; or 2) the participant is alive and medically ready for discharge as determined by the investigator.

Time frame:
Up to 29 days
Reported as:
Median · days
Time-to-sustained Recovery
daysPart 1: Molnupiravir 200 mgPart 1: Molnupiravir 400 mgPart 1: Molnupiravir 800 mgPart 1: PlaceboPart 2: MolnupiravirPart 2: Placebo
Time-to-sustained Recovery9.0 (7.0 to 10.0)9.0 (8.0 to 10.0)9.0 (8.0 to 11.0)9.0 (8.0 to 11.0)——
Statistical analysis
  • Part 1: Molnupiravir 200 mg vs Part 1: Placebo · Log Rank · p = 0.5620 · Hazard ratio (hr): 0.99 · 95% CI 0.68 to 1.45Based on Cox regression model with Efron's method of tie handling
  • Part 1: Molnupiravir 400 mg vs Part 1: Placebo · Log Rank · p = 0.3145 · Hazard ratio (hr): 1.13 · 95% CI 0.78 to 1.65Based on Cox regression model with Efron's method of tie handling
  • Part 1: Molnupiravir 800 mg vs Part 1: Placebo · Log Rank · p = 0.4894 · Hazard ratio (hr): 1.01 · 95% CI 0.69 to 1.47Based on Cox regression model with Efron's method of tie handling
PrimaryNumber of Participants With an Adverse Event (AE)

The number of participants with at least 1 AE is presented. An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

Time frame:
Up to 19 days (during treatment and 14-day follow-up)
Reported as:
Count of participants · Participants
Number of Participants With an Adverse Event (AE)
ParticipantsPart 1: Molnupiravir 200 mgPart 1: Molnupiravir 400 mgPart 1: Molnupiravir 800 mgPart 1: PlaceboPart 2: MolnupiravirPart 2: Placebo
Number of Participants With an Adverse Event (AE)40364546——
PrimaryNumber of Participants Who Discontinued Study Intervention Due to an AE

The number of participants discontinuing from study treatment due to an AE is presented. An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

Time frame:
Up to 5 days
Reported as:
Count of participants · Participants
Number of Participants Who Discontinued Study Intervention Due to an AE
ParticipantsPart 1: Molnupiravir 200 mgPart 1: Molnupiravir 400 mgPart 1: Molnupiravir 800 mgPart 1: PlaceboPart 2: MolnupiravirPart 2: Placebo
Number of Participants Who Discontinued Study Intervention Due to an AE0100——
SecondaryNumber of Participants With All-cause Mortality

The number of participants with all-cause mortality through Day 29 is presented. All-cause mortality is defined as death due to any cause. Any participants with an unknown survival status at Day 29 were imputed as deceased.

Time frame:
Up to 29 days
Reported as:
Count of participants · Participants
Number of Participants With All-cause Mortality
ParticipantsPart 1: Molnupiravir 200 mgPart 1: Molnupiravir 400 mgPart 1: Molnupiravir 800 mgPart 1: PlaceboPart 2: MolnupiravirPart 2: Placebo
Number of Participants With All-cause Mortality4541——
Statistical analysis
  • Part 1: Molnupiravir 200 mg vs Part 1: Placebo · Miettinen and Nurminen method · p = 0.1642 · Mean difference (final values): 4.1 · 95% CI -2.3 to 12.1Miettinen and Nurminen method. Unknown Day 29 survival status treated as failure.
  • Part 1: Molnupiravir 400 mg vs Part 1: Placebo · Miettinen and Nurminen method · p = 0.0900 · Mean difference (final values): 5.5 · 95% CI -1.1 to 13.9Miettinen and Nurminen method. Unknown Day 29 survival status treated as failure.
  • Part 1: Molnupiravir 800 mg vs Part 1: Placebo · Miettinen and Nurminen method · p = 0.1594 · Mean difference (final values): 4.2 · 95% CI -2.3 to 12.3Miettinen and Nurminen method. Unknown Day 29 survival status treated as failure.
SecondaryOdds of a More Favorable Response on Pulmonary Ordinal Outcome Score on Day 3

Pulmonary score is a score on an ordinal scale which focuses on respiratory sequalae based on oxygen requirements using 7 mutually exclusive categories. The score ranges from 1 ("can independently undertake personal usual activities with minimal or no symptoms") to 7 ("death") with a higher score indicating more severe respiratory sequalae. The number of participants at each score category is presented.

Time frame:
Day 3
Reported as:
Count of participants · Participants
Odds of a More Favorable Response on Pulmonary Ordinal Outcome Score on Day 3
ParticipantsPart 1: Molnupiravir 200 mgPart 1: Molnupiravir 400 mgPart 1: Molnupiravir 800 mgPart 1: PlaceboPart 2: MolnupiravirPart 2: Placebo
125202116——
22707——
321202325——
416161914——
579610——
61031——
70000——
Missing1102——
Statistical analysis
  • Part 1: Molnupiravir 200 mg vs Part 1: Placebo · Wald Chi-Square · p = 0.3623 · Odds ratio (or): 1.31 · 95% CI 0.73 to 2.35Based on the proportional odds model with Pulmonary score categories as the response variable. Due to sparse data, the final model includes only treatment as covariate. Confidence intervals (CIs) are based on Wald Chi-Square Test.
  • Part 1: Molnupiravir 400 mg vs Part 1: Placebo · Wald Chi-Square · p = 0.5714 · Odds ratio (or): 1.18 · 95% CI 0.66 to 2.12Based on the proportional odds model with Pulmonary score categories as the response variable. Due to sparse data, the final model includes only treatment as covariate. CIs are based on Wald Chi-Square Test.
  • Part 1: Molnupiravir 800 mg vs Part 1: Placebo · Wald Chi-Square · p = 0.9313 · Odds ratio (or): 0.97 · 95% CI 0.54 to 1.75Based on the proportional odds model with Pulmonary score categories as the response variable. Due to sparse data, the final model includes only treatment as covariate. CIs are based on Wald Chi-Square Test.
SecondaryOdds of a More Favorable Response on Pulmonary Ordinal Outcome Score on End of Treatment (EOT [Day 5])

Pulmonary score is a score on an ordinal scale which focuses on respiratory sequalae based on oxygen requirements using 7 mutually exclusive categories. The score ranges from 1 ("can independently undertake personal usual activities with minimal or no symptoms") to 7 ("death") with a higher score indicating more severe respiratory sequalae. The number of participants at each score category is presented.

Time frame:
EOT (Day 5)
Reported as:
Count of participants · Participants
Odds of a More Favorable Response on Pulmonary Ordinal Outcome Score on End of Treatment (EOT [Day 5])
ParticipantsPart 1: Molnupiravir 200 mgPart 1: Molnupiravir 400 mgPart 1: Molnupiravir 800 mgPart 1: PlaceboPart 2: MolnupiravirPart 2: Placebo
130222627——
26544——
317181516——
410141414——
57888——
61131——
70000——
Missing2525——
Statistical analysis
  • Part 1: Molnupiravir 200 mg vs Part 1: Placebo · Wald Chi-Square · p = 0.4398 · Odds ratio (or): 1.27 · 95% CI 0.70 to 2.30Based on the proportional odds model with Pulmonary score categories as the response variable. Due to sparse data, the final model includes only treatment as covariate. CIs are based on Wald Chi-Square Test.
  • Part 1: Molnupiravir 400 mg vs Part 1: Placebo · Wald Chi-Square · p = 0.6277 · Odds ratio (or): 0.86 · 95% CI 0.47 to 1.57Based on the proportional odds model with Pulmonary score categories as the response variable. Due to sparse data, the final model includes only treatment as covariate. CIs are based on Wald Chi-Square Test.
  • Part 1: Molnupiravir 800 mg vs Part 1: Placebo · Wald Chi-Square · p = 0.7069 · Odds ratio (or): 0.89 · 95% CI 0.49 to 1.62Based on the proportional odds model with Pulmonary score categories as the response variable. Due to sparse data, the final model includes only treatment as covariate. CIs are based on Wald Chi-Square Test.
SecondaryOdds of a More Favorable Response on Pulmonary Ordinal Outcome Score on Day 10

Pulmonary score is a score on an ordinal scale which focuses on respiratory sequalae based on oxygen requirements using 7 mutually exclusive categories. The score ranges from 1 ("can independently undertake personal usual activities with minimal or no symptoms") to 7 ("death") with a higher score indicating more severe respiratory sequalae. The number of participants at each score category is presented.

Time frame:
Day 10
Reported as:
Count of participants · Participants
Odds of a More Favorable Response on Pulmonary Ordinal Outcome Score on Day 10
ParticipantsPart 1: Molnupiravir 200 mgPart 1: Molnupiravir 400 mgPart 1: Molnupiravir 800 mgPart 1: PlaceboPart 2: MolnupiravirPart 2: Placebo
144393338——
24445——
3881410——
457810——
54354——
63033——
70300——
Missing5955——
Statistical analysis
  • Part 1: Molnupiravir 200 mg vs Part 1: Placebo · Wald Chi-Square · p = 0.2422 · Odds ratio (or): 1.48 · 95% CI 0.77 to 2.85Based on the proportional odds model with Pulmonary score categories as the response variable. Due to sparse data, the final model includes only treatment as covariate. CIs are based on Wald Chi-Square Test.
  • Part 1: Molnupiravir 400 mg vs Part 1: Placebo · Wald Chi-Square · p = 0.4789 · Odds ratio (or): 1.27 · 95% CI 0.66 to 2.44Based on the proportional odds model with Pulmonary score categories as the response variable. Due to sparse data, the final model includes only treatment as covariate. CIs are based on Wald Chi-Square Test.
  • Part 1: Molnupiravir 800 mg vs Part 1: Placebo · Wald Chi-Square · p = 0.6052 · Odds ratio (or): 0.85 · 95% CI 0.45 to 1.59Based on the proportional odds model with Pulmonary score categories as the response variable. Due to sparse data, the final model includes only treatment as covariate. CIs are based on Wald Chi-Square Test.
SecondaryOdds of a More Favorable Response on Pulmonary Ordinal Outcome Score on Day 15

Pulmonary score is a score on an ordinal scale which focuses on respiratory sequalae based on oxygen requirements using 7 mutually exclusive categories. The score ranges from 1 ("can independently undertake personal usual activities with minimal or no symptoms") to 7 ("death") with a higher score indicating more severe respiratory sequalae. The number of participants at each score category is presented.

Time frame:
Day 15
Reported as:
Count of participants · Participants
Odds of a More Favorable Response on Pulmonary Ordinal Outcome Score on Day 15
ParticipantsPart 1: Molnupiravir 200 mgPart 1: Molnupiravir 400 mgPart 1: Molnupiravir 800 mgPart 1: PlaceboPart 2: MolnupiravirPart 2: Placebo
145444142——
27225——
3661410——
43536——
52104——
64173——
70311——
Missing61144——
Statistical analysis
  • Part 1: Molnupiravir 200 mg vs Part 1: Placebo · Wald Chi-Square · p = 0.2644 · Odds ratio (or): 1.47 · 95% CI 0.75 to 2.88Based on the proportional odds model with Pulmonary score categories as the response variable. Due to sparse data, the final model includes only treatment as covariate. CIs are based on Wald Chi-Square Test.
  • Part 1: Molnupiravir 400 mg vs Part 1: Placebo · Wald Chi-Square · p = 0.2184 · Odds ratio (or): 1.55 · 95% CI 0.77 to 3.14Based on the proportional odds model with Pulmonary score categories as the response variable. Due to sparse data, the final model includes only treatment as covariate. CIs are based on Wald Chi-Square Test.
  • Part 1: Molnupiravir 800 mg vs Part 1: Placebo · Wald Chi-Square · p = 0.9771 · Odds ratio (or): 1.01 · 95% CI 0.53 to 1.94Based on the proportional odds model with Pulmonary score categories as the response variable. Due to sparse data, the final model includes only treatment as covariate. CIs are based on Wald Chi-Square Test.
SecondaryOdds of a More Favorable Response on Pulmonary Ordinal Outcome Score on Day 29

Pulmonary score is a score on an ordinal scale which focuses on respiratory sequalae based on oxygen requirements using 7 mutually exclusive categories. The score ranges from 1 ("can independently undertake personal usual activities with minimal or no symptoms") to 7 ("death") with a higher score indicating more severe respiratory sequalae. The number of participants at each score category is presented.

Time frame:
Day 29
Reported as:
Count of participants · Participants
Odds of a More Favorable Response on Pulmonary Ordinal Outcome Score on Day 29
ParticipantsPart 1: Molnupiravir 200 mgPart 1: Molnupiravir 400 mgPart 1: Molnupiravir 800 mgPart 1: PlaceboPart 2: MolnupiravirPart 2: Placebo
146474749——
22225——
34597——
45135——
50000——
62052——
74431——
Missing101436——
Statistical analysis
  • Part 1: Molnupiravir 200 mg vs Part 1: Placebo · Wald Chi-Square · p = 0.9945 · Odds ratio (or): 0.97 · 95% CI 0.46 to 2.06Based on the proportional odds model with Pulmonary score categories as the response variable. Due to sparse data, the final model includes only treatment as covariate. CIs are based on Wald Chi-Square Test.
  • Part 1: Molnupiravir 400 mg vs Part 1: Placebo · Wald Chi-Square · p = 0.3227 · Odds ratio (or): 1.50 · 95% CI 0.67 to 3.37Based on the proportional odds model with Pulmonary score categories as the response variable. Due to sparse data, the final model includes only treatment as covariate. CIs are based on Wald Chi-Square Test.
  • Part 1: Molnupiravir 800 mg vs Part 1: Placebo · Wald Chi-Square · p = 0.5200 · Odds ratio (or): 0.79 · 95% CI 0.39 to 1.61Based on the proportional odds model with Pulmonary score categories as the response variable. Due to sparse data, the final model includes only treatment as covariate. CIs are based on Wald Chi-Square Test.
SecondaryOdds of a More Favorable Response on Pulmonary+ Ordinal Outcome Score on Day 3

Pulmonary+ score is a score on an ordinal scale which is a 7-category assessment that captures the range of disease severity in hospitalized participants, including coagulation-related complications and respiratory dysfunction. The score ranges from 1 ("can independently undertake personal usual activities with minimal or no symptoms") to 7 ("death") with a higher score indicating more severe respiratory sequalae. The number of participants at each score category is presented.

Time frame:
Day 3
Reported as:
Count of participants · Participants
Odds of a More Favorable Response on Pulmonary+ Ordinal Outcome Score on Day 3
ParticipantsPart 1: Molnupiravir 200 mgPart 1: Molnupiravir 400 mgPart 1: Molnupiravir 800 mgPart 1: PlaceboPart 2: MolnupiravirPart 2: Placebo
125202116——
22707——
320202325——
416161914——
579610——
62031——
70000——
Missing1102——
Statistical analysis
  • Part 1: Molnupiravir 200 mg vs Part 1: Placebo · Wald Chi-Square · p = 0.4472 · Odds ratio (or): 1.25 · 95% CI 0.70 to 2.25Based on the proportional odds model with Pulmonary+ score categories as the response variable. Due to sparse data, the final model includes only treatment as covariate. CIs are based on Wald Chi-Square Test.
  • Part 1: Molnupiravir 400 mg vs Part 1: Placebo · Wald Chi-Square · p = 0.5714 · Odds ratio (or): 1.18 · 95% CI 0.66 to 2.12Based on the proportional odds model with Pulmonary+ score categories as the response variable. Due to sparse data, the final model includes only treatment as covariate. CIs are based on Wald Chi-Square Test.
  • Part 1: Molnupiravir 800 mg vs Part 1: Placebo · Wald Chi-Square · p = 0.9313 · Odds ratio (or): 0.97 · 95% CI 0.54 to 1.75Based on the proportional odds model with Pulmonary+ score categories as the response variable. Due to sparse data, the final model includes only treatment as covariate. CIs are based on Wald Chi-Square Test.
SecondaryOdds of a More Favorable Response on Pulmonary+ Ordinal Outcome Score on EOT (Day 5)

Pulmonary+ score is a score on an ordinal scale which is a 7-category assessment that captures the range of disease severity in hospitalized participants, including coagulation-related complications and respiratory dysfunction. The score ranges from 1 ("can independently undertake personal usual activities with minimal or no symptoms") to 7 ("death") with a higher score indicating more severe respiratory sequalae. The number of participants at each score category is presented.

Time frame:
EOT (Day 5)
Reported as:
Count of participants · Participants
Odds of a More Favorable Response on Pulmonary+ Ordinal Outcome Score on EOT (Day 5)
ParticipantsPart 1: Molnupiravir 200 mgPart 1: Molnupiravir 400 mgPart 1: Molnupiravir 800 mgPart 1: PlaceboPart 2: MolnupiravirPart 2: Placebo
130222627——
26544——
316181516——
410141414——
57888——
62131——
70000——
Missing2525——
Statistical analysis
  • Part 1: Molnupiravir 200 mg vs Part 1: Placebo · Wald Chi-Square · p = 0.5222 · Odds ratio (or): 1.22 · 95% CI 0.67 to 2.21Based on the proportional odds model with Pulmonary+ score categories as the response variable. Due to sparse data, the final model includes only treatment as covariate. CIs are based on Wald Chi-Square Test.
  • Part 1: Molnupiravir 400 mg vs Part 1: Placebo · Wald Chi-Square · p = 0.6277 · Odds ratio (or): 0.86 · 95% CI 0.47 to 1.57Based on the proportional odds model with Pulmonary+ score categories as the response variable. Due to sparse data, the final model includes only treatment as covariate. CIs are based on Wald Chi-Square Test.
  • Part 1: Molnupiravir 800 mg vs Part 1: Placebo · Wald Chi-Square · p = 0.7069 · Odds ratio (or): 0.89 · 95% CI 0.49 to 1.62Based on the proportional odds model with Pulmonary+ score categories as the response variable. Due to sparse data, the final model includes only treatment as covariate. CIs are based on Wald Chi-Square Test.
SecondaryOdds of a More Favorable Response on Pulmonary+ Ordinal Outcome Score on Day 10

Pulmonary+ score is a score on an ordinal scale which is a 7-category assessment that captures the range of disease severity in hospitalized participants, including coagulation-related complications and respiratory dysfunction. The score ranges from 1 ("can independently undertake personal usual activities with minimal or no symptoms") to 7 ("death") with a higher score indicating more severe respiratory sequalae. The number of participants at each score category is presented.

Time frame:
Day 10
Reported as:
Count of participants · Participants
Odds of a More Favorable Response on Pulmonary+ Ordinal Outcome Score on Day 10
ParticipantsPart 1: Molnupiravir 200 mgPart 1: Molnupiravir 400 mgPart 1: Molnupiravir 800 mgPart 1: PlaceboPart 2: MolnupiravirPart 2: Placebo
144393338——
24445——
3881410——
447810——
54344——
64043——
70300——
Missing5955——
Statistical analysis
  • Part 1: Molnupiravir 200 mg vs Part 1: Placebo · Wald Chi-Square · p = 0.2627 · Odds ratio (or): 1.46 · 95% CI 0.75 to 2.80Based on the proportional odds model with Pulmonary+ score categories as the response variable. Due to sparse data, the final model includes only treatment as covariate. CIs are based on Wald Chi-Square Test.
  • Part 1: Molnupiravir 400 mg vs Part 1: Placebo · Wald Chi-Square · p = 0.4789 · Odds ratio (or): 1.27 · 95% CI 0.66 to 2.44Based on the proportional odds model with Pulmonary+ score categories as the response variable. Due to sparse data, the final model includes only treatment as covariate. CIs are based on Wald Chi-Square Test.
  • Part 1: Molnupiravir 800 mg vs Part 1: Placebo · Wald Chi-Square · p = 0.5938 · Odds ratio (or): 0.84 · 95% CI 0.45 to 1.58Based on the proportional odds model with Pulmonary+ score categories as the response variable. Due to sparse data, the final model includes only treatment as covariate. CIs are based on Wald Chi-Square Test.
SecondaryOdds of a More Favorable Response on Pulmonary+ Ordinal Outcome Score on Day 15

Pulmonary+ score is a score on an ordinal scale which is a 7-category assessment that captures the range of disease severity in hospitalized participants, including coagulation-related complications and respiratory dysfunction. The score ranges from 1 ("can independently undertake personal usual activities with minimal or no symptoms") to 7 ("death") with a higher score indicating more severe respiratory sequalae. The number of participants at each score category is presented.

Time frame:
Day 15
Reported as:
Count of participants · Participants
Odds of a More Favorable Response on Pulmonary+ Ordinal Outcome Score on Day 15
ParticipantsPart 1: Molnupiravir 200 mgPart 1: Molnupiravir 400 mgPart 1: Molnupiravir 800 mgPart 1: PlaceboPart 2: MolnupiravirPart 2: Placebo
145444142——
27225——
3661410——
43536——
52104——
64173——
70311——
Missing61144——
Statistical analysis
  • Part 1: Molnupiravir 200 mg vs Part 1: Placebo · Wald Chi-Square · p = 0.2644 · Odds ratio (or): 1.47 · 95% CI 0.75 to 2.88Based on the proportional odds model with Pulmonary+ score categories as the response variable. Due to sparse data, the final model includes only treatment as covariate. CIs are based on Wald Chi-Square Test.
  • Part 1: Molnupiravir 400 mg vs Part 1: Placebo · Wald Chi-Square · p = 0.2184 · Odds ratio (or): 1.55 · 95% CI 0.77 to 3.14Based on the proportional odds model with Pulmonary+ score categories as the response variable. Due to sparse data, the final model includes only treatment as covariate. CIs are based on Wald Chi-Square Test.
  • Part 1: Molnupiravir 800 mg vs Part 1: Placebo · Wald Chi-Square · p = 0.9771 · Odds ratio (or): 1.01 · 95% CI 0.53 to 1.94Based on the proportional odds model with Pulmonary+ score categories as the response variable. Due to sparse data, the final model includes only treatment as covariate. CIs are based on Wald Chi-Square Test.
SecondaryOdds of a More Favorable Response on Pulmonary+ Ordinal Outcome Score on Day 29

Pulmonary+ score is a score on an ordinal scale which is a 7-category assessment that captures the range of disease severity in hospitalized participants, including coagulation-related complications and respiratory dysfunction. The score ranges from 1 ("can independently undertake personal usual activities with minimal or no symptoms") to 7 ("death") with a higher score indicating more severe respiratory sequalae. The number of participants at each score category is presented.

Time frame:
Day 29
Reported as:
Count of participants · Participants
Odds of a More Favorable Response on Pulmonary+ Ordinal Outcome Score on Day 29
ParticipantsPart 1: Molnupiravir 200 mgPart 1: Molnupiravir 400 mgPart 1: Molnupiravir 800 mgPart 1: PlaceboPart 2: MolnupiravirPart 2: Placebo
146474749——
22225——
34597——
45135——
50000——
62052——
74431——
Missing101436——
Statistical analysis
  • Part 1: Molnupiravir 200 mg vs Part 1: Placebo · Wald Chi-Square · p = 0.9445 · Odds ratio (or): 0.97 · 95% CI 0.46 to 2.06Based on the proportional odds model with Pulmonary+ score categories as the response variable. Due to sparse data, the final model includes only treatment as covariate. CIs are based on Wald Chi-Square Test.
  • Part 1: Molnupiravir 400 mg vs Part 1: Placebo · Wald Chi-Square · p = 0.3227 · Odds ratio (or): 1.50 · 95% CI 0.67 to 3.37Based on the proportional odds model with Pulmonary+ score categories as the response variable. Due to sparse data, the final model includes only treatment as covariate. CIs are based on Wald Chi-Square Test.
  • Part 1: Molnupiravir 800 mg vs Part 1: Placebo · Wald Chi-Square · p = 0.5200 · Odds ratio (or): 0.79 · 95% CI 0.39 to 1.61Based on the proportional odds model with Pulmonary+ score categories as the response variable. Due to sparse data, the final model includes only treatment as covariate. CIs are based on Wald Chi-Square Test.
SecondaryOdds of a More Favorable Response in the Clinical Risk of Mortality Category From the National Early Warning Score

The National Early Warning Score (Royal College of Physicians, 2012) assesses a participant's degree of illness as assessed by clinical risk prediction categories based on a set of vital sign measurements. There are 7 physiological parameters: respiration rate, oxygen saturation, supplemental oxygen, systolic blood pressure, pulse rate, level of consciousness, and temperature. A score of 0 to 3 was allocated to each parameter except supplemental oxygen use (score of 0 \[no\] or 2 \[yes\]) and level of consciousness (score of 0 or 3 with 0 = normal health condition and 3 = worst health condition). All scores were summed to get an aggregate score. Aggregate NEWS score ranged from 0 to 19, with higher scores meaning more severity/higher risk: low risk (score 0 to 4); low to medium risk (score of 3 in any individual parameter); medium risk (score 5 to 6); high risk (score 7 to 19). The number of participants at each aggregate risk category is presented.

Time frame:
EOT (Day 5)
Reported as:
Count of participants · Participants
Odds of a More Favorable Response in the Clinical Risk of Mortality Category From the National Early Warning Score
ParticipantsPart 1: Molnupiravir 200 mgPart 1: Molnupiravir 400 mgPart 1: Molnupiravir 800 mgPart 1: PlaceboPart 2: MolnupiravirPart 2: Placebo
Low57455255——
Medium88911——
High51183——
Missing3936——
Statistical analysis
  • Part 1: Molnupiravir 200 mg vs Part 1: Placebo · Wald Chi-Square · p = 0.8732 · Odds ratio (or): 1.07 · 95% CI 0.46 to 2.47Proportional odds model with National Early Warning Score (NEWS) categories as the response variable. Due to sparse data, the final model includes only treatment as covariate. CIs are based on Wald Chi-Square Test.
  • Part 1: Molnupiravir 400 mg vs Part 1: Placebo · Wald Chi-square · p = 0.1277 · Odds ratio (or): 0.54 · 95% CI 0.25 to 1.19Proportional odds model with NEWS categories as the response variable. Due to sparse data, the final model includes only treatment as covariate. CIs are based on Wald Chi-Square Test.
  • Part 1: Molnupiravir 800 mg vs Part 1: Placebo · Wald Chi-Square · p = 0.4326 · Odds ratio (or): 0.73 · 95% CI 0.33 to 1.61Proportional odds model with NEWS categories as the response variable. Due to sparse data, the final model includes only treatment as covariate. CIs are based on Wald Chi-Square Test.
SecondaryOdds of a More Favorable Response on WHO 11-point Ordinal Outcomes Score on a Scale on Day 3

The World Health Organization (WHO) outcome scale is an 11-point ordinal score that categorizes clinical progression. Score ranges from 0 ("uninfected") to 10 ("dead") with higher score indicating clinical progression. The number of participants at each score category is presented.

Time frame:
Day 3
Reported as:
Count of participants · Participants
Odds of a More Favorable Response on WHO 11-point Ordinal Outcomes Score on a Scale on Day 3
ParticipantsPart 1: Molnupiravir 200 mgPart 1: Molnupiravir 400 mgPart 1: Molnupiravir 800 mgPart 1: PlaceboPart 2: MolnupiravirPart 2: Placebo
00000——
10000——
21102——
31001——
427272124——
536364237——
679610——
70000——
80020——
91011——
100000——
Missing0000——
Statistical analysis
  • Part 1: Molnupiravir 200 mg vs Part 1: Placebo · Wald Chi-Square · p = 0.6830 · Odds ratio (or): 1.20 · 95% CI 0.50 to 2.88Based on the proportional odds model with WHO-11 score categories as the response variable. Due to sparse data, the final model includes only treatment as covariate. CIs are based on Wald Chi-Square Test.
  • Part 1: Molnupiravir 400 mg vs Part 1: Placebo · Wald Chi-Square · p = 1.000 · Odds ratio (or): 1.00 · 95% CI 0.42 to 2.39Based on the proportional odds model with WHO-11 score categories as the response variable. Due to sparse data, the final model includes only treatment as covariate. CIs are based on Wald Chi-Square Test.
  • Part 1: Molnupiravir 800 mg vs Part 1: Placebo · Wald Chi-Square · p = 0.8244 · Odds ratio (or): 0.90 · 95% CI 0.37 to 2.20Based on the proportional odds model with WHO-11 score categories as the response variable. Due to sparse data, the final model includes only treatment as covariate. CIs are based on Wald Chi-Square Test.
SecondaryOdds of a More Favorable Response on WHO 11-point Ordinal Outcomes Score on a Scale on EOT (Day 5)

The World Health Organization (WHO) outcome scale is an 11-point ordinal score that categorizes clinical progression. Score ranges from 0 ("uninfected") to 10 ("dead") with higher score indicating clinical progression. The number of participants at each score category is presented.

Time frame:
EOT (Day 5)
Reported as:
Count of participants · Participants
Odds of a More Favorable Response on WHO 11-point Ordinal Outcomes Score on a Scale on EOT (Day 5)
ParticipantsPart 1: Molnupiravir 200 mgPart 1: Molnupiravir 400 mgPart 1: Molnupiravir 800 mgPart 1: PlaceboPart 2: MolnupiravirPart 2: Placebo
02010——
12112——
23509——
30221——
429202725——
527312826——
67888——
70000——
81110——
90021——
100000——
Missing2523——
Statistical analysis
  • Part 1: Molnupiravir 200 mg vs Part 1: Placebo · Wald Chi-Square · p = 0.5022 · Odds ratio (or): 0.77 · 95% CI 0.36 to 1.64Based on the proportional odds model with WHO-11 score categories as the response variable. Due to sparse data, the final model includes only treatment as covariate. CIs are based on Wald Chi-Square Test.
  • Part 1: Molnupiravir 400 mg vs Part 1: Placebo · Wald Chi-Square · p = 0.5204 · Odds ratio (or): 0.78 · 95% CI 0.37 to 1.64Based on the proportional odds model with WHO-11 score categories as the response variable. Due to sparse data, the final model includes only treatment as covariate. CIs are based on Wald Chi-Square Test.
  • Part 1: Molnupiravir 800 mg vs Part 1: Placebo · Wald Chi-Square · p = 0.0991 · Odds ratio (or): 0.52 · 95% CI 0.24 to 1.13Based on the proportional odds model with WHO-11 score categories as the response variable. Due to sparse data, the final model includes only treatment as covariate. CIs are based on Wald Chi-Square Test.
SecondaryOdds of a More Favorable Response on WHO 11-point Ordinal Outcomes Score on a Scale on Day 10

The World Health Organization (WHO) outcome scale is an 11-point ordinal score that categorizes clinical progression. Score ranges from 0 ("uninfected") to 10 ("dead") with higher score indicating clinical progression. The number of participants at each score category is presented.

Time frame:
Day 10
Reported as:
Count of participants · Participants
Odds of a More Favorable Response on WHO 11-point Ordinal Outcomes Score on a Scale on Day 10
ParticipantsPart 1: Molnupiravir 200 mgPart 1: Molnupiravir 400 mgPart 1: Molnupiravir 800 mgPart 1: PlaceboPart 2: MolnupiravirPart 2: Placebo
03423——
110777——
226192221——
33478——
4816713——
51191411——
64253——
70010——
82003——
91020——
100300——
Missing5956——
Statistical analysis
  • Part 1: Molnupiravir 200 mg vs Part 1: Placebo · Wald Chi-Square · p = 0.6346 · Odds ratio (or): 1.18 · 95% CI 0.60 to 2.29Based on the proportional odds model with WHO-11 score categories as the response variable. Due to sparse data, the final model includes only treatment as covariate. CIs are based on Wald Chi-Square Test.
  • Part 1: Molnupiravir 400 mg vs Part 1: Placebo · Wald Chi-Square · p = 0.7596 · Odds ratio (or): 0.90 · 95% CI 0.46 to 1.75Based on the proportional odds model with WHO-11 score categories as the response variable. Due to sparse data, the final model includes only treatment as covariate. CIs are based on Wald Chi-Square Test.
  • Part 1: Molnupiravir 800 mg vs Part 1: Placebo · Wald Chi-Square · p = 0.8879 · Odds ratio (or): 0.95 · 95% CI 0.49 to 1.84Based on the proportional odds model with WHO-11 score categories as the response variable. Due to sparse data, the final model includes only treatment as covariate. CIs are based on Wald Chi-Square Test.
SecondaryOdds of a More Favorable Response on WHO 11-point Ordinal Outcomes Score on a Scale on Day 15

The World Health Organization (WHO) outcome scale is an 11-point ordinal score that categorizes clinical progression. Score ranges from 0 ("uninfected") to 10 ("dead") with higher score indicating clinical progression. The number of participants at each score category is presented.

Time frame:
Day 15
Reported as:
Count of participants · Participants
Odds of a More Favorable Response on WHO 11-point Ordinal Outcomes Score on a Scale on Day 15
ParticipantsPart 1: Molnupiravir 200 mgPart 1: Molnupiravir 400 mgPart 1: Molnupiravir 800 mgPart 1: PlaceboPart 2: MolnupiravirPart 2: Placebo
0108108——
11212911——
225252727——
37548——
44335——
54474——
62003——
70021——
83010——
90142——
100311——
Missing61245——
Statistical analysis
  • Part 1: Molnupiravir 200 mg vs Part 1: Placebo · Wald Chi-Square · p = 0.6002 · Odds ratio (or): 1.24 · 95% CI 0.55 to 2.82Based on the proportional odds model with WHO-11 score categories as the response variable. Due to sparse data, the final model includes only treatment as covariate. CIs are based on Wald Chi-Square Test.
  • Part 1: Molnupiravir 400 mg vs Part 1: Placebo · Wald Chi-Square · p = 0.4733 · Odds ratio (or): 1.37 · 95% CI 0.58 to 3.21Based on the proportional odds model with WHO-11 score categories as the response variable. Due to sparse data, the final model includes only treatment as covariate. CIs are based on Wald Chi-Square Test.
  • Part 1: Molnupiravir 800 mg vs Part 1: Placebo · Wald Chi-Square · p = 0.6220 · Odds ratio (or): 0.82 · 95% CI 0.38 to 1.78Based on the proportional odds model with WHO-11 score categories as the response variable. Due to sparse data, the final model includes only treatment as covariate. CIs are based on Wald Chi-Square Test.
SecondaryOdds of a More Favorable Response on WHO 11-point Ordinal Outcomes Score on a Scale on Day 29

The World Health Organization (WHO) outcome scale is an 11-point ordinal score that categorizes clinical progression. Score ranges from 0 ("uninfected") to 10 ("dead") with higher score indicating clinical progression. The number of participants at each score category is presented.

Time frame:
Day 29
Reported as:
Count of participants · Participants
Odds of a More Favorable Response on WHO 11-point Ordinal Outcomes Score on a Scale on Day 29
ParticipantsPart 1: Molnupiravir 200 mgPart 1: Molnupiravir 400 mgPart 1: Molnupiravir 800 mgPart 1: PlaceboPart 2: MolnupiravirPart 2: Placebo
025172922——
141379——
224211724——
33277——
40200——
51004——
60000——
70020——
82022——
90010——
104431——
Missing101446——
Statistical analysis
  • Part 1: Molnupiravir 200 mg vs Part 1: Placebo · Wald Chi-Square · p = 0.7871 · Odds ratio (or): 0.86 · 95% CI 0.28 to 2.60Based on the proportional odds model with WHO-11 score categories as the response variable. Due to sparse data, the final model includes only treatment as covariate. CIs are based on Wald Chi-Square Test.
  • Part 1: Molnupiravir 400 mg vs Part 1: Placebo · Wald Chi-Square · p = 0.9598 · Odds ratio (or): 0.97 · 95% CI 0.31 to 3.06Based on the proportional odds model with WHO-11 score categories as the response variable. Due to sparse data, the final model includes only treatment as covariate. CIs are based on Wald Chi-Square Test.
  • Part 1: Molnupiravir 800 mg vs Part 1: Placebo · Wald Chi-Square · p = 0.6670 · Odds ratio (or): 0.79 · 95% CI 0.27 to 2.31Based on the proportional odds model with WHO-11 score categories as the response variable. Due to sparse data, the final model includes only treatment as covariate. CIs are based on Wald Chi-Square Test.

Adverse events

Collected over Up to 7 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1: Molnupiravir 200 mg6/75 (8%)11/73 (15.1%)11/73 (15.1%)
Part 1: Molnupiravir 400 mg4/75 (5.3%)9/73 (12.3%)11/73 (15.1%)
Part 1: Molnupiravir 800 mg7/76 (9.2%)13/72 (18.1%)7/72 (9.7%)
Part 1: Placebo2/78 (2.6%)12/75 (16%)13/75 (17.3%)
Part 2: Molnupiravir———
Part 2: Placebo———
Most frequent serious events
Showing 10 of 37
Most frequent serious events
EventPart 1: Molnupiravir 200 mgPart 1: Molnupiravir 400 mgPart 1: Molnupiravir 800 mgPart 1: PlaceboPart 2: MolnupiravirPart 2: Placebo
COVID-19Infections and infestations7/734/735/726/75——
COVID-19 pneumoniaInfections and infestations0/731/733/725/75——
Respiratory failureRespiratory, thoracic and mediastinal disorders3/734/733/723/75——
Acute respiratory failureRespiratory, thoracic and mediastinal disorders3/730/732/722/75——
PneumoniaInfections and infestations0/731/732/720/75——
Pneumonia bacterialInfections and infestations1/730/732/720/75——
BacteraemiaInfections and infestations2/730/730/720/75——
Physical deconditioningGeneral disorders0/730/731/720/75——
CholestasisHepatobiliary disorders0/730/731/720/75——
Septic shockInfections and infestations0/731/731/720/75——
Most frequent other events
Most frequent other events
EventPart 1: Molnupiravir 200 mgPart 1: Molnupiravir 400 mgPart 1: Molnupiravir 800 mgPart 1: PlaceboPart 2: MolnupiravirPart 2: Placebo
Alanine aminotransferase increasedInvestigations4/735/737/728/75——
Aspartate aminotransferase increasedInvestigations3/735/735/723/75——
ConstipationGastrointestinal disorders5/732/730/725/75——
HyperglycaemiaMetabolism and nutrition disorders4/735/730/721/75——

Baseline characteristics

No participants were enrolled in Part 2 arms due to early study termination.

Age, Continuous
Age, Continuous(years)Part 1: Molnupiravir 200 mgPart 1: Molnupiravir 400 mgPart 1: Molnupiravir 800 mgPart 1: PlaceboPart 2: MolnupiravirPart 2: PlaceboTotal
Mean56.9 ± 14.257.0 ± 14.056.8 ± 13.757.1 ± 14.2——57.0 ± 14.0
Sex: Female, Male
Sex: Female, Male(Participants)Part 1: Molnupiravir 200 mgPart 1: Molnupiravir 400 mgPart 1: Molnupiravir 800 mgPart 1: PlaceboPart 2: MolnupiravirPart 2: PlaceboTotal
Female3234323400132
Male4341444400172
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part 1: Molnupiravir 200 mgPart 1: Molnupiravir 400 mgPart 1: Molnupiravir 800 mgPart 1: PlaceboPart 2: MolnupiravirPart 2: PlaceboTotal
Hispanic or Latino2732282700114
Not Hispanic or Latino4742464900184
Unknown or Not Reported1122006
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part 1: Molnupiravir 200 mgPart 1: Molnupiravir 400 mgPart 1: Molnupiravir 800 mgPart 1: PlaceboPart 2: MolnupiravirPart 2: PlaceboTotal
American Indian or Alaska Native0312006
Asian108410023
Native Hawaiian or Other Pacific Islander0010001
Black or African American14670018
White5852546300227
More than one race67950027
Unknown or Not Reported0110002
08

Study locations

89 sites
  • Kaiser Foundation Hospital - South Bay ( Site 1832)
    Harbor City, California 90710, United States
  • Cedars-Sinai Medical Center ( Site 1822)
    Los Angeles, California 90048, United States
  • University of California Davis Health ( Site 1809)
    Sacramento, California 95817, United States
  • University Of Florida ( Site 1810)
    Gainesville, Florida 32610, United States
  • Wellstar Kennestone Hospital ( Site 1801)
    Marietta, Georgia 30060, United States
  • Loretto Hospital ( Site 1838)
    Chicago, Illinois 60644, United States
  • LSU-HSC Shreveport ( Site 1824)
    Shreveport, Louisiana 71103, United States
  • Henry Ford Health System ( Site 1821)
    Detroit, Michigan 48202-2608, United States
  • University of Mississippi Medical Center ( Site 1846)
    Jackson, Mississippi 39216, United States
  • University of Nebraska Medical Center ( Site 1835)
    Omaha, Nebraska 68198, United States
  • University of New Mexico, Health Sciences Center ( Site 1806)
    Albuquerque, New Mexico 87131, United States
  • Carolinas Medical Center ( Site 1850)
    Charlotte, North Carolina 28203, United States
  • ECU Adult Specialty Care ( Site 1865)
    Greenville, North Carolina 27834, United States
  • Sanford Health ( Site 1851)
    Fargo, North Dakota 58122, United States
  • Temple University ( Site 1836)
    Philadelphia, Pennsylvania 19140, United States
  • CHRISTUS Institute for Innovation & Advanced Clinical Care ( Site 1864)
    Corpus Christi, Texas 78404, United States
  • Houston Methodist Hospital ( Site 1863)
    Houston, Texas 77030, United States
  • Swedish Medical Center ( Site 1812)
    Edmonds, Washington 98026, United States
  • Valley Medical Center ( Site 1815)
    Renton, Washington 98055, United States
  • Swedish Medical Center ( Site 1861)
    Seattle, Washington 98122, United States
  • Chronos Pesquisa Clínica ( Site 0105)
    Brasilia, Distrito Federal 72145-424, Brazil
  • Santa Casa de Misericordia de Belo Horizonte ( Site 0100)
    Belo Horizonte, Minas Gerais 30150-221, Brazil
  • Hospital de Clinicas da Universidade Federal do Parana ( Site 0104)
    Curitiba, Parana 80060-900, Brazil
  • Hospital Tacchini ( Site 0107)
    Bento Goncalves, Rio Grande Do Sul 95700-000, Brazil
  • FUNFARME Hospital de Base Centro Integrado de Pesquisa ( Site 0101)
    Sao Jose do Rio Preto, Sao Paulo 15090-000, Brazil
  • University Health Network - Toronto General Hospital ( Site 0201)
    Toronto, Ontario M5G 2N2, Canada
  • Hospital Clinico Fusat ( Site 0300)
    Rancagua, Libertador General Bernardo O Higgins 2820945, Chile
  • Clinica Universidad de los Andes ( Site 0301)
    Santiago, Region M. De Santiago 2820945, Chile
  • Hospital Sotero del Rio [Santiago, Chile] ( Site 0304)
    Santiago, Region M. De Santiago 8207257, Chile
  • Complejo Hospitalario San Jose ( Site 0306)
    Santiago, Region M. De Santiago 8380419, Chile
  • Servicio de Salud Sur Hospital Lucio Cordova ( Site 0305)
    Santiago, Region M. De Santiago 8900085, Chile
  • Hospital Pablo Tobon Uribe ( Site 0404)
    Medellin, Antioquia 050034, Colombia
  • Clinica de la Costa Ltda. ( Site 0402)
    Barranquilla, Atlantico 080020, Colombia
  • Oncomedica S.A. ( Site 0406)
    Monteria, Cordoba 230002, Colombia
  • Hospital Universitario San Ignacio ( Site 0401)
    Bogota, Distrito Capital De Bogota 110231, Colombia
  • Fundacion Cardiovascular de Colombia ( Site 0403)
    Bucaramanca, Santander 680003, Colombia
  • Fundacion Valle del Lili ( Site 0400)
    Cali, Valle Del Cauca 760032, Colombia
  • Groupe Hospitalier Pellegrin ( Site 0511)
    Bordeaux, Gironde 33000, France
  • Pitie Salpetriere University Hospital-Infectious Disease - Tropical Diseases ( Site 0504)
    Paris, Ile-de-France 75013, France
  • C.H.U. de Toulouse. Hopital de Purpan ( Site 0501)
    Toulouse, Midi-Pyrenees 31059, France
  • Centre Hospitalier de Tourcoing ( Site 0502)
    Tourcoing, Nord 59208, France
  • CHU Hopital Saint Antoine ( Site 0505)
    Paris, 75012, France
  • Hopital Bichat - Claude Bernard ( Site 0503)
    Paris, 75018, France
  • Rambam Medical Center ( Site 2102)
    Haifa, 3525408, Israel
  • Hadassah Medical Center. Ein Kerem ( Site 2103)
    Jerusalem, 9112001, Israel
  • Chaim Sheba Medical Center ( Site 2100)
    Ramat Gan, 5265601, Israel
  • ASST Fatebenefratelli-Ospedale Sacco ( Site 0601)
    Milano, 20157, Italy
  • Chungnam National University Hospital ( Site 2202)
    Daejeon, Taejon-Kwangyokshi 30515, Korea, Republic of
  • Inha University Hospital ( Site 2204)
    Incheon, 22332, Korea, Republic of
  • The Catholic University of Korea Eunpyeong St Mary s Hospital ( Site 2205)
    Seoul, 03312, Korea, Republic of
  • Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran ( Site 0802)
    Ciudad de mexico, Distrito Federal 14080, Mexico
  • Hospital Regional de Alta Especialidad del Bajio ( Site 0807)
    Leon, Guanajuato 37660, Mexico
  • Hospital Civil de Guadalajara Fray Antonio Alcalde ( Site 0800)
    Guadalajara, Jalisco 44280, Mexico
  • Hospital Universitario Dr. Jose Eleuterio Gonzalez ( Site 0803)
    Monterrey, Nuevo Leon 64460, Mexico
  • University of the Philippines-Philippine General Hospital ( Site 0900)
    Manila, National Capital Region 1000, Philippines
  • Lung Center of the Philippines ( Site 0902)
    Quezon City, National Capital Region 1100, Philippines
  • Wojewodzki Szpital Specjalistyczny im. dr. Wladyslawa Bieganskiego ( Site 1001)
    Lodz-Baluty, Lodzkie 91-347, Poland
  • Samodzielny Publiczny Szpital Kliniczny Nr 1 w Lublinie ( Site 1004)
    Lublin, Lubelskie 20-081, Poland
  • Centrum Medyczne Pratia, Mazowiecki Szpital Specjalistyczny, Oddział Obserwacyjno - Zakaźny ( Site 1
    Ostroleka, Mazowieckie 07-410, Poland
  • Centrum Medyczne w Lancucie Sp.zo.o. ( Site 1000)
    Lancut, Podkarpackie 37-100, Poland
  • Krasnogorsk City Hospital Number 1 ( Site 1119)
    Krasnogorsk, Moskovskaya Oblast 143408, Russian Federation
  • City Clinical Hospital #40 ( Site 1109)
    Moscow, Moskva 108814, Russian Federation
  • FSBI Central Hospital with Policlinics ( Site 1105)
    Moscow, Moskva 121359, Russian Federation
  • Moscow Clinical Hospital #52 ( Site 1103)
    Moscow, Moskva 123182, Russian Federation
  • City Hospital #40 ( Site 1113)
    Saint Petersburg, Sankt-Peterburg 197706, Russian Federation
  • City Pokrovskaya hospital ( Site 1116)
    Saint-Petersburg, Sankt-Peterburg 199106, Russian Federation
  • City Clinical Hospital #1 ( Site 1112)
    Smolensk, Smolenskaya Oblast 214006, Russian Federation
  • Republican Clinical Infectious Hospital n.a. A.F. Agafonov ( Site 1100)
    Kazan, Tatarstan, Respublika 420140, Russian Federation
  • IATROS International ( Site 1202)
    Bloemfontein, Free State 9301, South Africa
  • Wits Baragwanath Clinical Trial Site ( Site 1204)
    Soweto, Gauteng 2013, South Africa
  • TREAD Research ( Site 1201)
    Cape Town, Western Cape 7500, South Africa
  • Clinical Projects Research Centre ( Site 1205)
    Worcester, Western Cape 6850, South Africa
  • Hospital Universitari Vall d Hebron ( Site 1305)
    Barcelona, Cataluna 08035, Spain
  • Hospital Clinic ( Site 1304)
    Barcelona, 08036, Spain
  • Hospital Universitari Germans Trias i Pujol ( Site 1303)
    Barcelona, 08916, Spain
  • Hospital Universitario Gregorio Maranon ( Site 1302)
    Madrid, 28007, Spain
  • Hospital Universitario Ramon y Cajal ( Site 1301)
    Madrid, 28034, Spain
  • Hospital Universitario La Paz ( Site 1300)
    Madrid, 28046, Spain
  • Ivano-Frankivsk Regional Clinical Infectious Diseases Hospital ( Site 1605)
    Ivano-Frankivsk, Ivano-Frankivska Oblast 76007, Ukraine
  • CNE Central city clinical hospital of Ivano-Frankivsk city council ( Site 1604)
    Ivano-Frankivsk, Ivano-Frankivska Oblast 76018, Ukraine
  • MNE Ivano-Frankivsk Regional Phthisiology-Pulmonology Center ( Site 1603)
    Ivano-Frankivsk, Ivano-Frankivska Oblast 76018, Ukraine
  • CNPE of Kharkiv RC Regional Clinical Infectious Diseases Hospital ( Site 1606)
    Kharkiv, Kharkivska Oblast 61000, Ukraine
  • Сommunal non-com. Institution Oleksandrivska clinical hospital Kyiv ( Site 1600)
    Kyiv, Kyivska Oblast 01601, Ukraine
  • Odesa City Clinical Infectious Hospital ( Site 1611)
    Odesa, Odeska Oblast 65023, Ukraine
  • Communal Non-Commercial Enterprise Central City Hospital ( Site 1615)
    Rivne, Rivnenska Oblast 33018, Ukraine
  • Volyn Regional Clinical Hospital ( Site 1613)
    Lutsk, Volynska Oblast 43005, Ukraine
  • Royal Free London NHS Foundation Trust ( Site 1700)
    London, London, City Of NW3 2QG, United Kingdom
  • King's College Hospital ( Site 1705)
    London, London, City Of SE5 9RS, United Kingdom
  • North Manchester General Hospital ( Site 1701)
    Manchester, M8 5RB, United Kingdom
09

References and documents

Publications

  • Arribas JR, Bhagani S, Lobo SM, Khaertynova I, Mateu L, Fishchuk R, Park WY, Hussein K, Kim SW, Ghosn J, Brown ML, Zhang Y, Gao W, Assaid C, Grobler JA, Strizki J, Vesnesky M, Paschke A, Butterton JR, De Anda C. Randomized Trial of Molnupiravir or Placebo in Patients Hospitalized with Covid-19. NEJM Evid. 2022 Feb;1(2):EVIDoa2100044. doi: 10.1056/EVIDoa2100044. Epub 2021 Dec 16. PubMed 38319178 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2020 to primary completion in Aug 2021, 9 months.

Results were first posted in Aug 2022, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2020
First posted
Oct 5, 2020
StartActual
Oct 19, 2020
Primary completionActual
Aug 11, 2021
CompletionActual
Aug 11, 2021
Results first posted
Aug 16, 2022
Last update
Jan 17, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 17, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04575584
Responsible party
Sponsor
First posted
Oct 5, 2020
Start date
Oct 19, 2020
Primary completion
Aug 11, 2021
Completion
Aug 11, 2021
Results posted
Aug 16, 2022
Last update
Jan 17, 2023

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Molnupiravir

Start the discussion